U.S. genome editing company Precision Biosciences has priced its $132 million initial public offering (IPO).
The company priced the IPO between $15 to $17 per share.
Precision BioSciences has raised a total of $175.2 million in over four funding over 4 rounds.
Annually, the company books around $6 million in revenue.